NO20052866L - Imidazokinolinderivater som adenosin A3 reseptorligander - Google Patents

Imidazokinolinderivater som adenosin A3 reseptorligander

Info

Publication number: NO20052866L
Authority: NO; Norway
Prior art keywords: adenosine; receptor ligands; imidazoquinoline derivatives; imidazoquinoline; derivatives
Prior art date: 2002-11-15

Application number

NO20052866A

Other languages

English (en)

Norwegian (no)

Other versions

NO20052866D0 (no

Inventor

Judit Szeredi

Maria Balogh

Sandor Batori

Zoltan Kapui

Endre Mikus

Lajos T Nagy

Laszlo Balazs

Kinga Boer

Katalin Urban-Szabo

Katalin Gerber

Erzsebet Walcz

Peter Aranyi

Geza Timari

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-15

Filing date

2005-06-13

Publication date

2005-06-13

2005-06-13 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2005-06-13 Publication of NO20052866D0 publication Critical patent/NO20052866D0/no

2005-06-13 Publication of NO20052866L publication Critical patent/NO20052866L/no

Links

102000008161 Adenosine A3 Receptor Human genes 0.000 title abstract 2
108010060261 Adenosine A3 Receptor Proteins 0.000 title abstract 2
239000003446 ligand Substances 0.000 title abstract 2
RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
239000005557 antagonist Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Hematology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)

NO20052866A 2002-11-15 2005-06-13 Imidazokinolinderivater som adenosin A3 reseptorligander NO20052866L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU0203976A HUP0203976A3 (en)	2002-11-15	2002-11-15	Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
PCT/HU2003/000095 WO2004046146A1 (en)	2002-11-15	2003-11-11	Imidazoquinoline derivatives as adenosine a3 receptor ligands

Publications (2)

Publication Number	Publication Date
NO20052866D0 NO20052866D0 (no)	2005-06-13
NO20052866L true NO20052866L (no)	2005-06-13

Family

ID=90001561

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20052866A NO20052866L (no)	2002-11-15	2005-06-13	Imidazokinolinderivater som adenosin A3 reseptorligander

Country Status (34)

Country	Link
US (2)	US7419977B2 (is)
EP (1)	EP1560828B9 (is)
JP (1)	JP4533148B2 (is)
KR (1)	KR20050088291A (is)
CN (1)	CN1332960C (is)
AR (1)	AR041968A1 (is)
AT (1)	ATE325123T1 (is)
AU (1)	AU2003282263B2 (is)
BR (1)	BR0316355A (is)
CA (1)	CA2505910C (is)
CO (1)	CO5690577A2 (is)
CY (1)	CY1105180T1 (is)
DE (1)	DE60305058T2 (is)
DK (1)	DK1560828T3 (is)
EA (1)	EA007595B1 (is)
ES (1)	ES2263039T3 (is)
HR (1)	HRP20050540A2 (is)
HU (1)	HUP0203976A3 (is)
IL (1)	IL168516A (is)
IS (1)	IS2456B (is)
MA (1)	MA27501A1 (is)
ME (1)	MEP19008A (is)
MX (1)	MXPA05005198A (is)
NO (1)	NO20052866L (is)
NZ (1)	NZ540029A (is)
PL (1)	PL376837A1 (is)
PT (1)	PT1560828E (is)
RS (1)	RS51320B (is)
SI (1)	SI1560828T1 (is)
TN (1)	TNSN05133A1 (is)
TW (1)	TWI248934B (is)
UA (1)	UA78889C2 (is)
WO (1)	WO2004046146A1 (is)
ZA (1)	ZA200503807B (is)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUP0105406A3 (en) *	2001-12-21	2003-12-29	Sanofi Aventis	Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0203976A3 (en) *	2002-11-15	2004-08-30	Sanofi Aventis	Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
HUP0400812A2 (en) *	2004-04-19	2006-02-28	Sanofi Aventis	Crystalline forms of 2-amino-3-cyano-quinoline derivatives, process for their preparation and pharmaceutical compositions containing them
GT200600381A (es)	2005-08-25	2007-03-28		Compuestos organicos
US20090088403A1 (en) *	2007-05-07	2009-04-02	Randy Blakely	A3 adenosine receptors as targets for the modulation of central serotonergic signaling
HUP0700395A2 (en) *	2007-06-07	2009-03-02	Sanofi Aventis	Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
US9199102B2 (en)	2009-07-21	2015-12-01	Oradin Pharmaceutical Ltd.	A3 adenosine receptor ligands for modulation of pigmentation
CA3217159A1 (en)	2013-02-01	2014-08-07	Wellstat Therapeutics Corporation	Substituted quinazolin-4-amine compounds and pharmaceutical compositions thereof having anti-inflammatory, antifungal, antiparasitic and anticancer activity
KR101820909B1 (ko) *	2017-07-07	2018-01-23	퓨쳐메디신 주식회사	아데노신 유도체를 포함하는 만성신장질환 예방 및 치료용 약학적 조성물
WO2019055877A1 (en)	2017-09-15	2019-03-21	Forma Therapeutics, Inc.	TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
KR20250067962A (ko)	2018-06-29	2025-05-15	포르마 세라퓨틱스 인크.	Creb 결합 단백질(cbp)의 저해
EP3937936A4 (en) *	2019-03-15	2022-12-28	Forma Therapeutics, Inc.	INHIBITION OF CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB)
US12351577B2 (en)	2019-03-15	2025-07-08	Forma Therapeutics, Inc.	Inhibiting cyclic AMP-responsive element-binding protein (CREB)
US11801243B2 (en)	2020-09-23	2023-10-31	Forma Therapeutics, Inc.	Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en)	2020-09-23	2023-10-24	Forma Therapeutics, Inc.	Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4075343A (en) *	1976-09-13	1978-02-21	Pfizer Inc.	Anti-allergenic 5-alkoxyimidazo[1,2-A]quinoline-2-carboxylic acids and derivatives thereof
GB1596652A (en) *	1977-01-20	1981-08-26	Roussel Lab Ltd	Imidazo (1,2-a) quinoline-2-carboxylic acid and derivatives
FR2448541A1 (fr) *	1979-02-09	1980-09-05	Roussel Uclaf	Nouveaux derives de l'oxoimidazoquinoxaline et leurs sels, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US4644002A (en) *	1979-02-09	1987-02-17	Roussel Uclaf	Imidazo[2,1-C]quinolines, useful as antiallergic agents
SE441449B (sv) *	1979-02-09	1985-10-07	Roussel Uclaf	Heterocykliska derivat och farmaceutiska kompositioner innehallande dessa derivat
CA2336967C (en) *	1998-07-10	2010-06-29	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	A3 adenosine receptor antagonists
US6448253B1 (en) *	1998-09-16	2002-09-10	King Pharmaceuticals Research And Development, Inc.	Adenosine A3 receptor modulators
CN1207298C (zh) *	1999-09-28	2005-06-22	株式会社大塚制药工厂	三唑并嘌呤衍生物、含有该衍生物的药物组合物和腺苷a3受体亲和剂
US7160890B2 (en) *	1999-12-02	2007-01-09	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A3 receptor and uses thereof
IL155962A0 (en) *	2000-12-01	2003-12-23	Osi Pharm Inc	Compounds specific to adenosine a1, a2a, and a3 receptors and uses thereof
WO2002096879A1 (en) *	2001-05-31	2002-12-05	Sanofi-Synthelabo	Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
HUP0105406A3 (en) *	2001-12-21	2003-12-29	Sanofi Aventis	Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0105407A3 (en) *	2001-12-21	2004-04-28	Sanofi Aventis	Triazolo[1,5-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates
HUP0203976A3 (en) *	2002-11-15	2004-08-30	Sanofi Aventis	Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them

2002
- 2002-11-15 HU HU0203976A patent/HUP0203976A3/hu unknown
2003
- 2003-11-11 MX MXPA05005198A patent/MXPA05005198A/es active IP Right Grant
- 2003-11-11 JP JP2004552920A patent/JP4533148B2/ja not_active Expired - Fee Related
- 2003-11-11 WO PCT/HU2003/000095 patent/WO2004046146A1/en not_active Ceased
- 2003-11-11 CA CA2505910A patent/CA2505910C/en not_active Expired - Fee Related
- 2003-11-11 HR HR20050540A patent/HRP20050540A2/xx not_active Application Discontinuation
- 2003-11-11 NZ NZ540029A patent/NZ540029A/en not_active IP Right Cessation
- 2003-11-11 KR KR1020057008683A patent/KR20050088291A/ko not_active Abandoned
- 2003-11-11 PL PL376837A patent/PL376837A1/pl not_active Application Discontinuation
- 2003-11-11 PT PT03773882T patent/PT1560828E/pt unknown
- 2003-11-11 AT AT03773882T patent/ATE325123T1/de active
- 2003-11-11 RS YUP-2005/0364A patent/RS51320B/sr unknown
- 2003-11-11 EA EA200500830A patent/EA007595B1/ru unknown
- 2003-11-11 SI SI200330299T patent/SI1560828T1/sl unknown
- 2003-11-11 EP EP03773882A patent/EP1560828B9/en not_active Expired - Lifetime
- 2003-11-11 DE DE60305058T patent/DE60305058T2/de not_active Expired - Lifetime
- 2003-11-11 CN CNB2003801062293A patent/CN1332960C/zh not_active Expired - Fee Related
- 2003-11-11 BR BR0316355-5A patent/BR0316355A/pt not_active IP Right Cessation
- 2003-11-11 UA UAA200505875A patent/UA78889C2/uk unknown
- 2003-11-11 ES ES03773882T patent/ES2263039T3/es not_active Expired - Lifetime
- 2003-11-11 AU AU2003282263A patent/AU2003282263B2/en not_active Ceased
- 2003-11-11 DK DK03773882T patent/DK1560828T3/da active
- 2003-11-11 ME MEP-190/08A patent/MEP19008A/xx unknown
- 2003-11-14 AR ARP030104200A patent/AR041968A1/es unknown
- 2003-11-14 TW TW092131901A patent/TWI248934B/zh not_active IP Right Cessation
2005
- 2005-05-10 TN TNP2005000133A patent/TNSN05133A1/en unknown
- 2005-05-10 IL IL168516A patent/IL168516A/en not_active IP Right Cessation
- 2005-05-11 ZA ZA200503807A patent/ZA200503807B/en unknown
- 2005-05-16 US US11/130,429 patent/US7419977B2/en not_active Expired - Fee Related
- 2005-05-31 IS IS7874A patent/IS2456B/is unknown
- 2005-06-13 MA MA28334A patent/MA27501A1/fr unknown
- 2005-06-13 NO NO20052866A patent/NO20052866L/no not_active Application Discontinuation
- 2005-06-14 CO CO05057645A patent/CO5690577A2/es not_active Application Discontinuation
2006
- 2006-07-28 CY CY20061101054T patent/CY1105180T1/el unknown
2008
- 2008-06-17 US US12/140,512 patent/US7709489B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HUP0203976A3 (en)	2004-08-30
HUP0203976A2 (hu)	2004-07-28
JP4533148B2 (ja)	2010-09-01
TNSN05133A1 (en)	2007-05-14
EA007595B1 (ru)	2006-12-29
DE60305058T2 (de)	2006-12-14
US20080255110A1 (en)	2008-10-16
TW200413369A (en)	2004-08-01
WO2004046146A1 (en)	2004-06-03
IS2456B (is)	2008-11-15
PL376837A1 (pl)	2006-01-09
CO5690577A2 (es)	2006-10-31
TWI248934B (en)	2006-02-11
AR041968A1 (es)	2005-06-01
EP1560828A1 (en)	2005-08-10
MA27501A1 (fr)	2005-08-01
EP1560828B9 (en)	2007-02-14
RS51320B (sr)	2010-12-31
ATE325123T1 (de)	2006-06-15
IL168516A (en)	2011-05-31
CA2505910C (en)	2010-07-13
US20050234056A1 (en)	2005-10-20
SI1560828T1 (sl)	2006-08-31
UA78889C2 (en)	2007-04-25
AU2003282263B2 (en)	2009-05-14
MEP19008A (en)	2010-06-10
BR0316355A (pt)	2005-09-27
DK1560828T3 (da)	2006-09-04
EA200500830A1 (ru)	2005-10-27
JP2006515572A (ja)	2006-06-01
ES2263039T3 (es)	2006-12-01
IS7874A (is)	2005-05-31
KR20050088291A (ko)	2005-09-05
HU0203976D0 (en)	2003-01-28
RS20050364A (sr)	2007-08-03
NO20052866D0 (no)	2005-06-13
US7419977B2 (en)	2008-09-02
CN1332960C (zh)	2007-08-22
CY1105180T1 (el)	2010-03-03
DE60305058D1 (de)	2006-06-08
MXPA05005198A (es)	2005-08-18
HK1077819A1 (en)	2006-02-24
NZ540029A (en)	2007-01-26
US7709489B2 (en)	2010-05-04
HRP20050540A2 (en)	2005-08-31
ZA200503807B (en)	2006-08-30
CN1726213A (zh)	2006-01-25
AU2003282263A1 (en)	2004-06-15
EP1560828B1 (en)	2006-05-03
CA2505910A1 (en)	2004-06-03
PT1560828E (pt)	2006-08-31

Legal Events

Date	Code	Title	Description
2012-08-06	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
BR0016396A (pt)	2002-08-20	Novos antagonistas do receptor p2x7 para uso no tratamento de doenças inflamatórias, imunes ou cardiovasculares
NO20054082D0 (no)	2005-09-02	Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander
NO20032252D0 (no)	2003-05-19	Piperazinylpyrazinforbindelser som agonist eller antagonist av serotonin 5HT-2-reseptor
DK1381363T3 (da)	2005-04-18	Imidazo[1,2-a]pyridinderivater som mGluR5-antagonister
DK1337518T3 (da)	2009-10-19	Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren
ATE301653T1 (de)	2005-08-15	Pyrazolopyridine
DK1277754T3 (da)	2005-11-14	Imidazopyridinderivater
ATE296826T1 (de)	2005-06-15	Pyrazolo(1,5)pyridinderivate
NO20052993D0 (no)	2005-06-17	4,5-diaryltiazolderivater som CB-1 ligander.
DK1175401T3 (da)	2005-11-14	Piperazinderivater, der er nyttige som CCR5-antagonister
ATE302775T1 (de)	2005-09-15	Carbolinderivate
NO20041504L (no)	2004-05-13	Lactamderivater som antagonister for humane 11CBY reseptorer.
ATE332301T1 (de)	2006-07-15	Antivirale pyrazolopyridin verbindungen
WO2003095455A3 (en)	2003-12-24	Substituted pyrazolopyrimidines
ATE422198T1 (de)	2009-02-15	Arylsulfonylnaphthalinderivate als 5ht2a- antagonisten
CY1107875T1 (el)	2013-06-19	Παραγωγα αμινοκινολινης και η χρηση τους ως συνδετες των α3 αδενοσινης
ATE300541T1 (de)	2005-08-15	Pyrazolopyridinderivate
ATE346067T1 (de)	2006-12-15	Carbolinderivate
TNSN05133A1 (en)	2007-05-14	Imidazoquinoline derivatives as adenosine a3 receptor ligands
NZ552137A (en)	2009-08-28	New 4-benzylidene-piperidin derivatives
WO2005007103A3 (en)	2005-10-27	Use of parthenolide derivatives as antileukemic and cytotoxic agents
DE60315826D1 (de)	2007-10-04	Neue verbindungen
WO2004067703A3 (en)	2004-11-04	5ht7 antagonists and inverse agonists
NO20063354L (no)	2006-09-21	Nikotinacetylcholinreseptorligander
DE60222465D1 (de)	2007-10-25	Pyrazolopyridin-derivate als antiherpesmittel